Zepbound for Sleep Apnea

The FDA recently approved Zepbound (tirzepatide) as the first-ever medication for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. This approval, announced on December 20, 2024, is a game-changer for OSA management, especially for those who find traditional therapies like CPAP machines challenging.

This article explores how Zepbound works, the research behind its FDA approval, and its potential impact on sleep apnea treatment. You’ll also learn about its benefits and key considerations for those considering this new option.

What is Obstructive Sleep Apnea (OSA)?

OSA is a common sleep disorder that affects approximately 39 million US adults. It occurs when the upper airway becomes partly (hypopnea) or completely (apnea) blocked during sleep, causing breathing to stop and start repeatedly. The American Academy of Sleep Medicine (AASM) defines hypopnea as follows:

• • A reduction in breathing by at least 30% for over 10 seconds, and oxygen levels in the blood drop by 4% or more.
  • A reduction in breathing by at least 30% for over 10 seconds, along with either a drop in oxygen levels of 3% or more or a brief awakening (detected in a sleep study).

Symptoms of OSA often include:

• • Loud or heavy snoring
  • Daytime fatigue or excessive sleepiness
  • Abrupt breathing interruptions
  • Dry mouth
  • Persistent headaches
  • Interrupted sleep

If left untreated, OSA can lead to serious health complications, including mental health issues, reduced quality of life, car accidents, slowed growth in children, and high blood pressure during pregnancy.

Obesity and Its Role in Sleep Apnea

Obesity and OSA are closely connected, with both sharing similar risk factors like genetics, gender, age, and lifestyle habits such as poor diet and lack of exercise. These two conditions affect each other in a cycle.

A study found that gaining 10% more body weight increased the severity of OSA by 32% and made people six times more likely to develop moderate-to-severe OSA. Meanwhile, losing 10% of body weight reduced the severity of OSA by 26%.

Obesity makes OSA worse because fat around the throat narrows the airway and makes it more likely to collapse during sleep. On the other hand, OSA can lead to obesity because it disrupts hormones that control hunger, causing people to eat more. Fatigue and mood changes from OSA can also make people less active, leading to further weight gain.

How Zepbound Supports OSA Management

Zepbound works by activating specific hormones in the body, GLP-1 and GIP, which work to reduce appetite and control food intake. It was first approved for chronic weight management in adults with obesity or those overweight with related health conditions.

As mentioned earlier, significant weight loss is fundamental in alleviating OSA symptoms, as excess body weight often narrows the airway and increases the risk of obstruction during sleep. By promoting weight reduction, Zepbound addresses one of the primary causes of OSA.

Clinical Trial Insights on Zepbound for Sleep Apnea (OSA)

The approval of Zepbound was based on results from a year-long study called SURMOUNT-OSA. This study tested Zepbound (10 mg and 15 mg doses) in adults with moderate-to-severe OSA who had obesity. Some participants used Zepbound with positive airway pressure (PAP) therapy, the current gold standard for OSA, while others did not.

For those not using PAP therapy, Zepbound reduced breathing interruptions by 25 times per hour, compared to only 5 fewer interruptions with a placebo. When combined with PAP therapy, Zepbound reduced breathing interruptions by 29 times per hour, compared to 6 fewer interruptions with a placebo.

After a year, 42% of those on Zepbound alone and 50% of those on Zepbound with PAP therapy had their OSA improve to mild or non-symptomatic levels. By comparison, only 16% (without PAP) and 14% (with PAP) on a placebo saw similar improvements.

Furthermore, participants on Zepbound lost an average of 45 lbs (18% of their body weight). Those using Zepbound with PAP therapy lost an average of 50 lbs (20% of their body weight). In contrast, those on a placebo lost only 4-6 pounds.

Expert Perspectives on Zepbound for OSA

The American Academy of Sleep Medicine (AASM) supports the FDA’s approval of Zepbound for sleep apnea but notes it’s not suitable for everyone. In a December 21 statement, the AASM explained that while excess weight is a leading cause of sleep apnea, other factors, like jaw or airway structure, can also contribute.

They also stressed that Zepbound requires ongoing weight loss to remain effective in reducing sleep apnea symptoms, making it most useful as part of a broader health plan.

During an interview with Verywell, Dr. Jorge Moreno, an internal medicine physician at Yale Medicine and board-certified in obesity medicine, described the data supporting Zepbound as “pretty good and robust.”

He noted that many people find CPAP machines difficult to use because of discomfort, irritation, or concerns about how the device might affect their appearance or interactions with bed partners. For these individuals, Dr. Moreno suggested that Zepbound could be a helpful alternative or used alongside PAP therapy.

Considerations for Patients

While Zepbound is a promising option, it’s not without side effects. Common ones include nausea, diarrhea, constipation, and injection site reactions. There’s also a potential risk for thyroid C-cell tumors, so it’s not recommended for people with certain thyroid conditions or a family history of medullary thyroid cancer.

Patients considering Zepbound should consult with their healthcare providers to determine eligibility.

Will Insurance Cover Zepbound for Sleep Apnea (OSA)?

Insurance coverage for Zepbound as a treatment for OSA may vary widely at this time, especially since the approval for this indication is still very recent. While some insurers might eventually provide coverage, it’s likely that many plans haven’t yet adjusted their policies to reflect this new use of Zepbound.

Insurers that do consider coverage for Zepbound may require prior authorization, demonstrating its medical necessity. To find out more:

• • Contact your insurance provider directly to inquire about coverage.
  • Consult your healthcare provider for assistance with prior authorization if needed.
  • Explore patient assistance programs if you encounter high costs.

What It Means for Your Health

If you wake up feeling tired or feel very sleepy during the day, talk to your doctor about testing for OSA. Getting diagnosed can help you find the right treatment, like Zepbound, and lower your risk of serious health problems like heart disease, diabetes, and depression. Better sleep can lead to a healthier, happier life.

Frequently Asked Questions